Publication | Closed Access

GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome

Down SyndromeHematological MalignancyOncologyMedicineMixed-phenotype Acute LeukemiaHematologyTransient LeukemiaPathologyAdult T-cell Leukemia-lymphomaMolecular DiagnosticsCell BiologyCancer ResearchMinimal Residual DiseaseMyeloid Neoplasia